05 Study To Europe

Lytix Biopharma AS

14/11/2022 07:05

Nov 14 (Reuters) - Lytix Biopharma AS  LYTIX.OL :
    * LYTIX BIOPHARMA ANNOUNCES EXPANSION OF THE ATLAS-IT-05
STUDY TO
EUROPE
    * ANNOUNCES SITE ACTIVATION FOR ATLAS-IT-05 STUDY IN THREE
EUROPEAN COUNTRIES
    * ATLAS-IT-05 IS A PHASE II COMBINATION STUDY EVALUATING
LTX-315
AND PEMBROLIZUMAB IN PATIENTS WITH ADVANCED MELANOMA
    * STUDY WAS INITIATED AT MD ANDERSON CANCER CENTER IN 2021
AND IS
CURRENTLY ONGOING IN US
    * REGULATORY APPLICATION IN EUROPE WAS APPROVED IN Q3 2022,
AND
EFFORTS TO INITIATE RECRUITMENT OF PATIENTS IS ONGOING WITH AIM
TO COMPLETE ENROLLMENT IN STUDY IN EARLY 2023

Source text for Eikon:  ID:nObiXl8pWa 
Further company coverage:  LYTIX.OL 
 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))